Study #2021-1194
A phase Ib study to evaluate the safety and preliminary efficacy of IL6-receptor antibody sarilumab in combination with antiPD1 antibody cemiplimab for patients with non-small cell lung cancer.
MD Anderson Study Status
Not Accepting
Treatment Agent
Cemiplimab, Kevzara (Sarilumab)
Description
To learn if the combination of sarilumab (also called Kevzara) and cemiplimab can help to control EGFR- or LKB1/STK11-mutant NSCLC.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lung Cancer
Study phase:
Phase I
Physician name:
Xiuning Le
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-424-0935
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.